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Essential Role of CCR6 in Directing Activated T Cells
to the Skin during Contact Hypersensitivity
Timothy J. Paradis1, Susan H. Cole1, Robin T. Nelson1 and Ronald P. Gladue1
CCR6 is expressed in a number of dermatological inflammatory diseases. Here, we report that mice sensitized
with the hapten oxazolone had increased numbers of CCR6þ T cells in the draining lymph nodes. Using
CCR6/ mice, we assessed the role of CCR6 on the development of contact hypersensitivity. After hapten
sensitization and re-challenge, ear swelling in CCR6/ animals was reduced 80% as compared with wild-type
(WT) control mice. This decreased level of inflammation was not related to an inhibition in T-cell activation,
because CCR6/ lymph node cells from sensitized mice produced threefold higher levels of IFN-g in culture
than cells from sensitized WT mice and, when these cells were directly injected into the site of hapten
challenge, induced a robust inflammatory response. However, intravenous injection of CCR6/ lymph node
cells from sensitized mice were unable to prime naive mice to re-challenge whereas cells from primed WTmice
were able to sensitize animals. These results suggest that CCR6 plays an important role in directing the
trafficking of activated T cells into the skin and suggests that a CCR6 antagonist could be useful to treat skin-
mediated inflammatory reactions.
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INTRODUCTION
Contact hypersensitivity (CHS) is an epidermal T cell-
mediated inflammatory response to low-molecular-weight
haptens (Enk, 1997; Watanabe et al., 2002). It is one of the
most prevalent diseases encountered in the work place
(Kucenic and Belsito, 2002). CHS can be divided into two
distinct phases known as the sensitization (or afferent) and
elicitation (or efferent) phases (Grabbe and Schwarz, 1998;
Watanabe et al., 2002).
During the sensitization phase, Langerhans cells in the
skin become activated after taking up antigen and migrate to
the draining lymph nodes (DLNs) where they present hapten
to naive T cells (Saint-Mezard et al., 2004). Once stimulated,
the hapten-specific effector/memory T cells migrate back
into circulation and function as a monitoring system against
future hapten exposure (Saint-Mezard et al., 2004). Upon
re-exposure, these effector cells migrate to the site of hapten
challenge and induce an inflammatory reaction.
The receptors responsible for recruiting leukocytes to the
skin during the elicitation phase of contact hypersensitivity
are unclear. One potential receptor is CCR6, a CC chemokine
receptor that interacts with CCL20 (Schutyser et al., 2003).
Studies have demonstrated that CCL20 is expressed by
keratinocytes in the skin (Schutyser et al., 2003). In addition,
CCR6 has been shown to be expressed by epidermal
Langerhans cells and effector/memory T lymphocytes
(Charbonnier et al., 1999; Liao et al., 1999). Skin biopsies
from psoriatic lesions and atopic dermatitis patients have
shown increased expression of both CCR6 and CCL20
(Dieu-Nosjean et al., 2000; Homey et al., 2000a, b;
Nakayama et al., 2001; Schmuth et al., 2002). Further,
plasma levels of CCL20 have been shown to be increased in
patients with atopic dermatitis and CCR6 mRNA has been
reported to be increased in peripheral blood mononuclear
cells from psoriasis patients (Dieu-Nosjean et al., 2000;
Homey et al., 2000a, b; Nakayama et al., 2001).
In this study, we assessed the role of CCR6 in the
development of CHS. We demonstrate that CCR6 is critical
for directing immune cell migration into the skin, the
magnitude of which depends on the hapten used, but did
not impair T-cell activation. Our findings suggest an
important role for CCR6 in the efferent arm of CHS and
suggest that CCR6 antagonists may be useful to treat atopic
dermatitis.
RESULTS
Characterization of CCR6/ animals
CCR6/ mice were viable and the deletion was transferred
in a Mendelian manner to subsequent generations. As
shown in Figure 1, CCR6 mRNA from DLNs was only
found in the wild-type (WT) mice and not in CCR6/
animals. In addition, no cell surface expression of CCR6
was detected in CCR6/ animals by FACS analysis (data
not shown).
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CCR6 expression in the DLN of mice sensitized with oxazolone
In the first study, we assessed the effects of oxazolone
sensitization on the expression of CCR6þ cells in the DLN of
WT mice. Whereas CCR6 was only expressed on 5% of
the cells in naive WT mice, 4 days after sensitization
with oxazolone, CCR6 expression increased 47-fold to
36% of the cells (Figure 2a and b, respectively). As expected,
CCR6/ mice lacked evidence of CCR6 expression (data not
shown).
DLN cells from hapten-sensitized mice produce more IFN-c
in vitro than lymph node cells isolated from naive mice
We next determined the impact of CCR6 deletion on T-cell
priming by measuring IFN-g production. Lymph node
cultures from non-sensitized animals contained o5 pg/ml of
IFN-g (Figure 3). In contrast, cells obtained from WT and
CCR6/ oxazolone-sensitized animals produced 15 and
49 pg/ml IFN-g, respectively. These results suggest that CCR6
deletion did not impair T-cell activation and may have
slightly enhanced it.
CHS responses are impaired in CCR6/ knockout mice
We next evaluated the role of CCR6 on the inflammatory
response after secondary challenge. As shown in Figure 4
using oxazolone as the hapten and in Figures 5 and 6 using
2,4-dinitrofluorobenzene (DNFB) as hapten, CCR6/ mice
had a significant reduction in ear swelling as compared with
WT animals when re-challenged. Interestingly, when com-
paring the responses between the two haptens, the suppres-
sive effects were greater in oxazolone-sensitized mice
(fivefold) as compared with both the 0.05 and 0.5% re-
challenged DNFB-sensitized mice (2- and 1.7-fold, respec-
tively) at 24 hours. In fact, the inhibition observed when
DNFB was used as the hapten was both dose- and time-
dependent. At 24 hours after challenge, a 45–50% reduction
in inflammation was seen with mice sensitized to 0.5 and
0.05% DNFB, respectively. This reduction in inflammation in
the CCR6/mice was still evident in the 0.05% DNFB group
at 72 hours after re-challenge. However, the difference
between WT and CCR6/ animals was not statistically
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Figure 1. CCR6 mRNA is not expressed in CCR6/ mice. Total mRNA
was isolated from the lymph nodes of WT and CCR6/ mice and analyzed
for the expression of CCR6 by reverse transcription-PCR. CCR6 mRNA results
are shown for CCR6/ and WT mice versus a GAPDH control.
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Figure 2. CCR6 expression was increased in the DLNs of WT mice after
sensitization with hapten. WT mice were painted with 100 ml of a 3%
oxazolone solution on the abdomen. Four days later DLN were removed and
single-cell suspension stained using a PE-conjugated anti-CCR6 antibody.
The hatched lines in the histograms represent anti-CCR6-PE binding to DLN
cells, whereas the solid lines represent cell reactivity with the isotype-
matched control-PE antibody from a representative experiment. (a) CCR6
expression in lymph nodes of naive mice. (b) CCR6 expression 4 days after
hapten sensitization.
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Figure 3. Lymph node cells from oxazolone-sensitized CCR6 / mice
produced more IFN-c in vitro than WT controls.WT and CCR6/mice were
sensitized with 100 ml of a 3% oxazolone solution on the surface of the
abdomen. Five days later, DLNs were harvested, single-cell suspensions made
and cultured at 5106/ml for 24 and 48 hours. IFN-g levels in the culture
supernatants were determined by ELISA at 24 and 48hours. Data presented
are from a representative experiment showing the mean7SD (5 mice/group).
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different on days 2 and 3 in those animals receiving 0.5%
DNFB (Figures 5 and 6, respectively).
CCR6/ oxazolone-sensitized DLN can transfer CHS to
challenged naive WT mice only when injected at the site of
hapten
Next, we wanted to determine whether the cells present in
the lymph node of oxazolone-sensitized CCR6/ animals
had the ability to transfer sensitivity to naive animals. In the
first study, we injected cells directly into a site of oxazolone
challenge in the footpad. As shown in Figure 7, sensitized
cells from both CCR6/ or WT animals induced a robust
swelling response in naive CCR6/ and WT mice following
hapten challenge, indicating that cells were activated and
capable of inducing inflammation. We next administered the
hapten-sensitized cells from CCR6/ and WT animals
intravenously to naive mice. The results show a significant
reduction in ability of sensitized CCR6/ T cells to prime
mice to re-challenge as compared with cells obtained from
sensitized WT mice after intravenous injection (Figure 8).
DISCUSSION
We show that CCR6 plays an important role in mediating skin
inflammation during contact hypersensitivity. Our data
suggest that the afferent arm of CHS in CCR6/ mice was
intact because T-cell priming was maintained after hapten
sensitization. In contrast, the efferent arm where T cells
migrate to a site of hapten challenge appeared to have been
inhibited because intravenously injected primed CCR6/
T cells failed to sensitize naive animals. This defect in T-cell
migration in CCR6/ animals could be overcome by directly
injecting sensitized cells into the site of hapten challenge
confirming that T-cell activation was not altered in these
animals. Taken together, these results suggest that CCR6 is a
crucial T-cell chemotactic receptor mediating skin inflamma-
tion during contact hypersensitivity.
T-cell priming after hapten sensitization was not only
unimpaired in CCR6/ mice, but may have been enhanced.
This is suggested by the increased secretion of IFN-g by
sensitized lymph node cells from CCR6/ mice versus
WT controls. This may be related to effects on dendritic
cell trafficking. After hapten challenge, dendritic cells have
been reported to increase CCR7 expression and decrease
CCR6 expression during DC maturation and migration
into lymph node areas to prime T cells (Carramolino et al.,
1999; Watanabe et al., 2002). Once in the lymph node,
dendritic cells can re-express CCR6, which may play a role
in directing them back into circulation. If this is the case,
in the absence of CCR6, hapten-presenting dendritic cells
may have been retained within the lymph nodes thus
intensifying local T-cell activity. This hypothesis would
require further investigation.
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Figure 4. CHS to oxazolone challenge is significantly decreased in CCR6 /
mice. WT and CCR6/ mice were sensitized to hapten by painting 100ml of
a 3% solution of oxazolone on the abdomen. Subsequently, on day 4, mice
were challenged on the ear with 20 ml of a 1% oxazolone solution and the
inflammatory response was measured 24 hours later by measuring the change
in ear thickness. Data are from a representative experiment showing
individual data points for 5 mice/group. *Po0.05.
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Figure 5. CHS to 0.05% DNFB sensitization in CCR6/mice is significantly
reduced as compared with WT controls. WT and CCR6/ mice were
sensitized to DNFB by a topical application of a 100 ml of 0.05% DNFB
solution on the shaved abdomen. Five days later, the sensitized mice were
challenged on the ear with 20 ml of a 0.02% solution of DNFB, and the
change in ear thickness was measured 24, 48, and 72hours later. Data show
inflammation in each individual animal using 10 mice/group for the WT mice
and 9 mice/group for the CCR6/ mice. *Po0.05.
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Another, perhaps more likely explanation for the increased
level of T-cell activity observed in CCR6/ animals could be
directly related to the retention of activated T cells in the lymph
nodes and peripheral circulation. Under normal conditions,
hapten-laden dendritic cells migrate into lymph nodes after
sensitization and activate T cells. CCR6þ T cells may then
either leave the lymph node areas and circulate as quiescent
memory T cells or migrate into skin for hapten surveillance
(Watanabe et al., 2002; Saint-Mezard et al., 2004). CCL20 has
been reported to be produced at low levels by normal
keratinocytes, which may mediate this activity (Charbonnier
et al., 1999). In the absence of CCR6, hapten-sensitized T cells
may be retained in the lymph nodes, which may explain the
increased level of T-cell activity in CCR6/-sensitized lymph
node cells. A previous study supports our observations
showing an increased T-cell proliferative response to DNFB
in CCR6/ animals (Varona et al., 2001).
Although T-cell activity was increased in CCR6/ mice,
lymph node cells taken from sensitized CCR6/ mice were
unable to elicit contact hypersensitivity in naive mice when
injected intravenously. This suggests that CCR6 is crucial for
the migration of these cells to the skin after hapten challenge.
Recent papers have shown high levels of CCL20 in inflamed
skin (Dieu-Nosjean et al., 2000; Nakayama et al., 2001;
Schmuth et al., 2002; Schutyser et al., 2003). This observa-
tion, and the inability of CCR6/ T cells to elicit contact
hypersensitivity when administered intravenously but full
capacity to elicit a response when injected locally, suggests a
critical role for this chemokine receptor in directing T cells
into areas of epidermal inflammation.
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Figure 6. CHS to 0.5% DNFB sensitization in CCR6/ mice is significantly
decreased as compared with WT controls. WT and CCR6/ mice were
sensitized to DNFB by a topical application of a 100 ml of 0.5% DNFB
solution on the shaved abdomen. Five days later, the mice were challenged
with 20ml of a 0.2% solution of DNFB and monitored for inflammation 24,
48, and 72 hours later. Data show inflammation in each individual animal
using 10 mice/group for the WT mice and 9 mice/group for the CCR6/
mice. *Po0.05.
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Figure 7. CCR6/ oxazolone-sensitized DLN cells can transfer CHS to
naive WT mice when injected directly into the site of hapten challenge.
Donor WT and CCR6/ mice were either untreated or sensitized topically
with 100ml of a 3% oxazolone on the abdomen. On day 4, effector DLN cells
were harvested and naive WT mice either received 107 effector cells
subcutaneously into the footpad or no cells, and then were immediately
challenged with 1% oxazolone (20 ml). The change in footpad thickness was
measured 24hours later. The swelling was significantly greater in those mice
receiving sensitized effectors cells as compared with those mice receiving no
effector cells or naive DLN cells. The data represent the mean71 SD for a
representative experiment. *Po0.05.
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Figure 8. CCR6/ oxazolone-sensitized DLN cells injected intravenously
into hapten-challenged WT mice are unable to transfer CHS. Sensitized DLN
cells from WT or CCR6/ mice were harvested and 107 sensitized effector
cells were injected intravenously into naive WT mice, which were
immediately challenged with 20 ml of a 1.0% solution of oxazolone on the
ear. The change in ear thickness was measured 24 hours later. Data represent
the mean inflammation for each individual animal using five mice/treatment
group. *Po0.05.
www.jidonline.org 631
TJ Paradis et al.
CCR6 and Contact Sensitivity
A previous study has reported that CHS is enhanced in
CCR6/ animals after DNFB challenge (Varona et al., 2001).
There are several explanations for this discrepancy. In the
study by Varona et al. (2001) only a high dose of DNFB was
used as the hapten, whereas we observed that suppression in
CHS was influenced by DNFB dose. In our study, inhibition
was observed with the lower 0.05% dose, whereas at the 0.5%
dose, a decreased swelling was only transiently observed at
24hours after hapten application and was slightly increased by
72hours in the CCR6/ mice. As such, by only using a high-
dose level of DNFB, the study by Varona et al. (2001)
suggested exacerbation rather than inhibition. A second
consideration for the discrepancy could be the differences in
the genetic make up of the mice. Our animals were fully
backcrossed onto a C57BL/6 background, whereas those used
by Varona et al. (2001) were on a mixed 129/C57BL/6
background. It has been reported that strain differences can
affect the degree of hapten-induced CHS and this requires
further investigation in our model (Steinbrink et al., 1996).
The dose-related effect observed when DNFB was used as
the hapten suggest that CCR6 is one of many receptors
involved in coordinating effector T-lymphocyte recruitment
into the skin during CHS. Other potential receptors expressed
on skin-homing T lymphocytes include CCR4 and CCR10
(Campbell et al., 1999; Reiss et al., 2001; Kim, 2004;
Santamaria-Babi, 2004). Evidence for their role is shown by
an increase in their numbers at the sites of epidermal
inflammation (Campbell et al., 1999; Homey et al., 2002).
In addition, the CCR10 ligand CCL27 produced by keratino-
cytes is increased in inflamed skin (Morales et al., 1999;
Homey et al., 2000a, b). Therefore, additional chemokine
receptors may play a role in CHS. Future studies will address
this hypothesis using clinically relevant allergens as the type,
amount, strength, and duration of exposure will vary
tremendously in a clinical situation.
In summary, our data suggest that CCR6 plays an
important role in the generation of CHS. In particular, this
receptor appears to be critical for directing the trafficking of
effector lymphocytes from the DLN after activation into sites
of hapten exposure in the skin. However, the data demon-
strate the complexity of CHS and suggest that the role played
by CCR6 is one of many factors determining the outcome of
the response. Nonetheless, CCR6 inhibition may be good
target for immune therapy of epidermal inflammatory
diseases. Whether it can be used as a stand-alone approach
or would be more effective in combination therapy due to the
complexity of the disease needs further evaluation.
MATERIALS AND METHODS
Mice
CCR6/ mice were obtained from Deltagen (San Carlos, CA) and
backcrossed nine generations onto a C57BL/6 background. WT
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor,
ME). All animals were maintained in a pathogen-free environment
and were allowed access to food and water ad libitum. Mice were
acclimated for at least 7 days before experiments. In vivo procedures
underwent veterinary review and approval by the Pfizer Institutional
Animal Care and Use Committee.
Analysis of CCR6 expression
The deletion of the CCR6 gene was verified by reverse transcription-
PCR. RNA was obtained from lymph node cells collected from the
CCR6/ and WT animals by the NucleoSpins protocol with Dnase
treatment (Clontech, Mountain View, CA). RT-PCR was performed
using both random hexamers and oligo-dT primers and AMV reverse
transcriptase (Roche Applied Science, Indianapolis, IN) and 5 mg of
RNA. Mouse CCR6-specific primers used for PCR were sense primer:
50-ATGAATTCCACAGAGTCCTA-30 hybridizing at bases 1–20 in the
cDNA and antisense primer: 50-AATAAACGTCATACAACACGG-30
hybridizing at bases 914–934. Thirty cycles of PCR were performed
with an annealing temperature of 551C using Perkin Elmer AmpliTaq
polymerase (Boston, MA) and the final concentrations for each of the
components were 1mM of each primer, 2mM MgCl2, 50mM dNTPs,
and 3ml of cDNA as template.
Contact hypersensitivity
Mice were sensitized and challenged with hapten as described
previously (Varona et al., 2001). Preliminary studies showed that a
3% oxazolone (Sigma Chemical, St Louis, MA) and a 0.5% DNFB
(Sigma Chemical, St Louis, MA) resulted in comparable degrees of
inflammation. Therefore, these concentrations of hapten, along with
an additional dose of 0.05% DNFB, were chosen for this study.
Briefly, mice were sensitized topically on the shaved abdomen with
100ml of either 3% oxazolone (Sigma Chemical) suspended in 100%
ethanol or 100ml of a 0.05 or 0.5% solution of DNFB (Sigma
Chemical) solution in acetone/olive oil (4:1). Animals were then
challenged topically (20 ml) with the same hapten on the right ear at
the times and concentrations specified. Ear thickness was measured
using a digital caliper (Thornwood, NY) and the degree of hapten-
induced inflammation was determined by subtracting the ear
thickness of the non-challenged ear from the thickness of the ear
challenged with the hapten.
Cytokine measurement
DLN cells were obtained from WT and CCR6/ mice 4 days after
sensitization with oxazolone and cultured in RPMI medium contain-
ing 10% fetal bovine serum, L-glutamine (2mM), HEPES (10mM),
penicillin (100U/ml), streptomycin (50 mg/ml), and 2-mercaptoetha-
nol (50 mM) all purchased from GibcoBRL (Grand Island, NY).
Supernatants were collected at various times and assessed for IFN-g
by ELISA (R&D Systems, Minneapolis, MN).
Determination of CCR6 expression on DLNs by flow cytometry
DLN cells were obtained from sensitized mice and stained with
phycoerythrin-conjugated anti-mouse CCR6 (R&D Systems) or a
control antibody at 41C for 30minutes. After staining, cells were
washed three times with 3ml of a cold wash buffer consisting of PBS
containing 2% FBS and 0.01% sodium azide. Next, cells were
resuspended in cold wash solution and 10,000 events were collected
and analyzed using CellQuest acquisition and analysis software
using a Becton Dickinson FACSCalibur (San Jose, CA). The data are
expressed as the mean channel fluorescence.
Adoptive transfer of hapten-sensitized effector cells to naive
mice
DLN cells were collected from WT and CCR6/ mice 4 days after
sensitization with oxazolone. Next, naive mice were challenged
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with 20ml of hapten on the ear or footpad and then 107 DLN cells
from sensitized animals were adoptively transferred either intra-
venously or directly into a site of hapten challenge (footpad).
The magnitude of inflammation was determined by measuring the
increase in ear swelling using a Starrett digital caliper.
Statistics
Significance was determined using the Student’s t-test. A P-value of
o0.05 was considered significant.
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